MedTrace Logo

Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye

NCT02951975 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 246

Last updated 2019-08-02

No results posted yet for this study

Summary

This observational study will evaluate the safety, efficacy, characteristics of patients, characteristics of physicians and quality of life in patients who are prescribed OZURDEX® as treatment for non-infectious uveitis of the posterior segment of the eye in France.

Conditions

  • Non-infectious Uveitis

Interventions

DRUG

dexamethasone intravitreal implant

Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Nathalie Mesnard · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-25
Primary Completion
2018-11-28
Completion
2018-12-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02951975 on ClinicalTrials.gov